The <scp>MSA</scp> Atrophy Index (<scp>MSA</scp>‐<scp>AI</scp>): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy
The MSA-AI is a promising imaging biomarker for diagnosis and monitoring disease progression in MSA. These findings require validation in larger, independent cohorts.
Authors
- Matthew P. Landman (ORCID: https://orcid.org/0000-0003-0441-5329)
- Italo Biaggioni (ORCID: https://orcid.org/0000-0001-7667-7083)
- Cynthia S. Wong (ORCID: https://orcid.org/0000-0003-3576-1232)
- Manus J. Donahue (ORCID: https://orcid.org/0000-0002-4123-9275)
- Daniel O. Claassen (ORCID: https://orcid.org/0000-0002-9853-4902)
- Paula Trujillo (ORCID: https://orcid.org/0000-0001-9753-7071)
- Amy Cooper (ORCID: https://orcid.org/0000-0003-3354-0364)
- Margaret Bradbury
- David Stamler
- Kilian Hett (ORCID: https://orcid.org/0000-0001-8831-4247)
- Jessica Iregui
- Amy E. Brown (ORCID: https://orcid.org/0000-0001-5752-9835)
Institutions
- Spark Therapeutics (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1002/acn3.70106
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Institutes of Health
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke